On February 12, 2021, the U.S. Food and Drug Administration approved trilaciclib (Cosela™), a parenteral inhibitor of cyclin-dependent kinase (CDK), to prevent myelosuppression when administered prior to chemotherapy administration. The approval is currently limited to the use of trilaciclib before treatment with platinum- and etoposide-containing regimens and topotecan-containing regimens for treatment of extensive-stage small cell lung cancer.
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education